About GenIbet
GenIbet is a Healthcare company based in Oeiras (Portugal) founded in 2006, and was acquired by Recipharm in February 2022. Microbial and mammalian-derived products are developed and manufactured by GenIbet. Its chief executive, as recorded, is Raquel Fortunato. GenIbet offers products and services including Biologics Manufacturing, RNA Manufacturing, ATMP Fill and Finish, and Plasmid Manufacturing. Its focus areas include Biopharma Outsourcing, CDMO, Biologics and Mammalian Cell Line. Its legal entity is Recipharm AB.
Company details
GenIbet was established in 2006 in Oeiras, Portugal, within the biotechnology sector. Microbial and mammalian-derived products are created through specialized services such as cell line development, process development, and analytical development. Manufacturing activities cover mammalian and insect cells, recombinant proteins, viruses, and biomass from bacteria or yeast. Operations remain focused on biopharmaceutical production and research support in Europe.
- Headquarters Oeiras, Portugal
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website genibet.com
- Social LinkedIn YouTube
- Acquired by Recipharm (Feb 2022)
- Legal Name Recipharm Ab
Products & Services of GenIbet
GenIbet offers a comprehensive portfolio of products and services, including Biologics Manufacturing, RNA Manufacturing, ATMP Fill and Finish, and Plasmid Manufacturing.
Production of biologics for drug development and therapies
Creation of RNA therapies and lipid nanoparticles
Final processing of advanced therapy medicinal products
Production of plasmid DNA for genetic applications
Apps and channels of GenIbet
its YouTube channel Recipharm CDMO has 308 subscribers and 30 videos.
Videos from GenIbet
The most watched videos on GenIbet's YouTube channel, Recipharm CDMO (308 subscribers). Click a video to play it here.
More on Recipharm CDMO.
Funding Insights of GenIbet
- Total Rounds 5
- Last Round Grant — $13,210
- First Round $787,024
(Mar 2015)
- Investors Count 1
All 5 funding rounds of GenIbet with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2020 | $13,210 | Grant | – | – | |
| Jun 2019 | $964,473 | Grant | – | – | |
| May 2017 | $151,202 | Grant | – | – | |
| Jan 2017 | $115,572 | Grant | – | – | |
| Mar 2015 | $787,024 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in GenIbet
GenIbet has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Recipharm and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Pharmaceutical development and manufacturing services are offered contractually. | 1995 | recipharm.com | Jordbro, Sweden |
Investor details for GenIbet
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GenIbet
1 people are tracked at GenIbet (1 in leadership).
| Name | Role | Group |
|---|---|---|
Raquel Fortunato | CEO | Leadership |
Complete people profiles for GenIbet
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of GenIbet
4 dated milestones of GenIbet across 16 years, from founding to its latest funding, stage changes and deals.
- Founded GenIbet is founded.
- Funding First funding round of $787K.
- Funding Latest funding round, Grant, of $13K.
- Exit Acquired by Recipharm.
Web traffic of GenIbet
Websites that share an audience with GenIbet (genibet.com).
Websites whose visitors overlap most with GenIbet. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
google.fr | google.fr | 100% | #273 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genibet
Complete news archive for GenIbet
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GenIbet
GenIbet was founded in 2006 and raised its 1st funding round 9 years after it was founded.
GenIbet is headquartered in Oeiras, Portugal.
Raquel Fortunato is the CEO of GenIbet, as recorded in our data.
GenIbet was established in 2006 in Oeiras, Portugal, within the biotechnology sector. Microbial and mammalian-derived products are created through specialized services such as cell line development, process development, and analytical development. Manufacturing activities cover mammalian and insect cells, recombinant proteins, viruses, and biomass from bacteria or yeast. Operations remain focused on biopharmaceutical production and research support in Europe.
GenIbet offers Biologics Manufacturing, RNA Manufacturing, ATMP Fill and Finish, and Plasmid Manufacturing.
GenIbet has 2 investors. Key investors include Recipharm, and European Union.
GenIbet operates through Recipharm Ab.
Yes. GenIbet was acquired by Recipharm in February 2022.